tetano
Editor, Senior Moderator
PLoS One
. 2025 Nov 3;20(11):e0335609.
doi: 10.1371/journal.pone.0335609. eCollection 2025. Research to evaluate safety and impact of long COVID intervention with Ensitrelvir for National Cohort (RESILIENCE Study): A protocol for a randomized, double-blind, placebo-controlled trial
Keiji Konishi[SUP] 1 2 3 [/SUP], Shungo Yamamoto[SUP] 2 4 5 [/SUP], Ryuichi Minoda Sada[SUP] 2 4 5 [/SUP], Kento Asano[SUP] 6 [/SUP], Daisuke Onozuka[SUP] 1 2 [/SUP], Shintaro Tanaka[SUP] 7 [/SUP], Shogo Miyazawa[SUP] 8 [/SUP], Masahiro Kinoshita[SUP] 9 [/SUP], Satoshi Kutsuna[SUP] 1 2 4 5 [/SUP]
Affiliations
This study was registered with the Japan Registry of Clinical Trials on February 16, 2024 (jRCTs051230184, https://jrct.mhlw.go.jp/en-latest-detail/jRCTs051230184).
Copyright: © 2025 Konishi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
PubMed Disclaimer
Conflict of interest statement
Keiji Konishi, Daisuke Onozuka, and Satoshi Kutsuna have received research support from Shionogi & Co., Ltd., Tokyo, Japan. Shungo Yamamoto, Ryuichi Minoda Sada, Kento Asano declare no competing interests. Shintaro Tanaka, Shogo Miyazawa, and Masahiro Kinoshita are full-time employees of Shionogi & Co., Ltd., and may hold stock in the company. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
. 2025 Nov 3;20(11):e0335609.
doi: 10.1371/journal.pone.0335609. eCollection 2025. Research to evaluate safety and impact of long COVID intervention with Ensitrelvir for National Cohort (RESILIENCE Study): A protocol for a randomized, double-blind, placebo-controlled trial
Keiji Konishi[SUP] 1 2 3 [/SUP], Shungo Yamamoto[SUP] 2 4 5 [/SUP], Ryuichi Minoda Sada[SUP] 2 4 5 [/SUP], Kento Asano[SUP] 6 [/SUP], Daisuke Onozuka[SUP] 1 2 [/SUP], Shintaro Tanaka[SUP] 7 [/SUP], Shogo Miyazawa[SUP] 8 [/SUP], Masahiro Kinoshita[SUP] 9 [/SUP], Satoshi Kutsuna[SUP] 1 2 4 5 [/SUP]
Affiliations
- PMID: 41183079
- DOI: 10.1371/journal.pone.0335609
This study was registered with the Japan Registry of Clinical Trials on February 16, 2024 (jRCTs051230184, https://jrct.mhlw.go.jp/en-latest-detail/jRCTs051230184).
Copyright: © 2025 Konishi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
PubMed Disclaimer
Conflict of interest statement
Keiji Konishi, Daisuke Onozuka, and Satoshi Kutsuna have received research support from Shionogi & Co., Ltd., Tokyo, Japan. Shungo Yamamoto, Ryuichi Minoda Sada, Kento Asano declare no competing interests. Shintaro Tanaka, Shogo Miyazawa, and Masahiro Kinoshita are full-time employees of Shionogi & Co., Ltd., and may hold stock in the company. This does not alter our adherence to PLOS ONE policies on sharing data and materials.